Neuropeptide S alleviates neuropathic pain by activating LH-vlPAG orexinergic circuit in rats.
Background
Neuropathic pain is a debilitating chronic condition arising from nervous system damage, presenting a significant clinical challenge due to limited effective treatment options. Current pharmacological approaches often fall short, providing incomplete relief and carrying substantial side effects. The Neuropeptide S (NPS) system is known to modulate pain and affective states, but its precise mechanisms in neuropathic pain remain largely unexplored. This study investigates the role of the lateral hypothalamic (LH) orexinergic neurons, which are activated by NPS and implicated in various physiological processes including stress-induced analgesia, as a potential mediator of NPS's pain-modulatory actions.
Study Design
Researchers induced neuropathic pain in rats using a chronic constriction injury (CCI) model of the sciatic nerve. They then investigated the pain response via paw withdrawal latency (PWL) and paw withdrawal threshold (PWT). The study involved intra-LH injection of Neuropeptide S to CCI rats, with a control arm receiving a vehicle. To elucidate the mechanism, they also administered the NPSR antagonist SHA-68 intra-LH and the orexin-1/2 receptor antagonist SB-334867 into the ventrolateral periaqueductal gray (vlPAG), nucleus accumbens (NAc), and ventral tegmental area (VTA). Expression of NPS protein and NPSR mRNA in the LH was assessed, alongside cFos expression in orexin neurons and GABA/glutamate levels in the vlPAG. Retrograde tracing with Fast Blue was used to map orexinergic projections.
Results
Intra-LH administration of Neuropeptide S to CCI rats significantly increased both
paw withdrawal latency (PWL)andpaw withdrawal threshold (PWT), indicating a robust antinociceptive effect.
Why It Matters
This research identifies a novel and specific neural circuit, the LH-vlPAG orexinergic pathway, through which Neuropeptide S can alleviate neuropathic pain. Targeting the NPS system or its downstream orexinergic signaling could offer a promising non-opioid strategy for chronic pain management. This mechanistic insight is crucial for developing new therapeutic interventions that address the underlying pathology rather than just symptoms. While this is a preclinical rat study, it lays the groundwork for future translational research, potentially leading to novel compounds or delivery methods that modulate this specific pathway. Further studies are needed to determine optimal dosing, long-term efficacy, and safety profiles before clinical application.